vs

Side-by-side financial comparison of ClearPoint Neuro, Inc. (CLPT) and Red Cat Holdings, Inc. (RCAT). Click either name above to swap in a different company.

ClearPoint Neuro, Inc. is the larger business by last-quarter revenue ($10.4M vs $9.6M, roughly 1.1× Red Cat Holdings, Inc.). On growth, Red Cat Holdings, Inc. posted the faster year-over-year revenue change (988.2% vs 34.0%). ClearPoint Neuro, Inc. produced more free cash flow last quarter ($-12.1M vs $-24.5M).

ClearPoint Neuro, Inc. is a medical technology firm specializing in precision neurology solutions. It develops and commercializes intraoperative navigation, targeting and delivery systems for minimally invasive brain surgeries, neurological disorder treatments, and CNS therapy development for global clinical and biopharmaceutical partners.

Mega Cat Studios is an American video game development and publishing company located in Pittsburgh, Pennsylvania. It was founded in 2015 by James Deighan, Nick Mann, and Zack Manko.

CLPT vs RCAT — Head-to-Head

Bigger by revenue
CLPT
CLPT
1.1× larger
CLPT
$10.4M
$9.6M
RCAT
Growing faster (revenue YoY)
RCAT
RCAT
+954.3% gap
RCAT
988.2%
34.0%
CLPT
More free cash flow
CLPT
CLPT
$12.4M more FCF
CLPT
$-12.1M
$-24.5M
RCAT

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CLPT
CLPT
RCAT
RCAT
Revenue
$10.4M
$9.6M
Net Profit
$-16.0M
Gross Margin
61.5%
6.6%
Operating Margin
-67.7%
-181.7%
Net Margin
-166.0%
Revenue YoY
34.0%
988.2%
Net Profit YoY
-29.0%
EPS (diluted)
$-0.26
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLPT
CLPT
RCAT
RCAT
Q4 25
$10.4M
Q3 25
$8.9M
$9.6M
Q2 25
$9.2M
Q1 25
$8.5M
$1.6M
Q4 24
$7.8M
$0
Q3 24
$8.1M
Q2 24
$7.9M
Q1 24
$7.6M
$5.8M
Net Profit
CLPT
CLPT
RCAT
RCAT
Q4 25
Q3 25
$-5.9M
$-16.0M
Q2 25
$-5.8M
Q1 25
$-6.0M
$-23.1M
Q4 24
$-13.3M
Q3 24
$-5.0M
Q2 24
$-4.4M
Q1 24
$-4.1M
$-5.5M
Gross Margin
CLPT
CLPT
RCAT
RCAT
Q4 25
61.5%
Q3 25
63.2%
6.6%
Q2 25
60.3%
Q1 25
60.5%
-52.2%
Q4 24
61.3%
Q3 24
59.7%
Q2 24
63.5%
Q1 24
59.2%
18.8%
Operating Margin
CLPT
CLPT
RCAT
RCAT
Q4 25
-67.7%
Q3 25
-59.5%
-181.7%
Q2 25
-61.6%
Q1 25
-72.6%
-765.7%
Q4 24
-72.5%
Q3 24
-63.5%
Q2 24
-60.1%
Q1 24
-55.2%
-76.0%
Net Margin
CLPT
CLPT
RCAT
RCAT
Q4 25
Q3 25
-66.5%
-166.0%
Q2 25
-63.3%
Q1 25
-71.0%
-1418.9%
Q4 24
Q3 24
-61.2%
Q2 24
-56.1%
Q1 24
-54.3%
-93.9%
EPS (diluted)
CLPT
CLPT
RCAT
RCAT
Q4 25
$-0.26
Q3 25
$-0.21
$-0.16
Q2 25
$-0.21
Q1 25
$-0.22
$-0.27
Q4 24
$-0.20
Q3 24
$-0.18
Q2 24
$-0.16
Q1 24
$-0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLPT
CLPT
RCAT
RCAT
Cash + ST InvestmentsLiquidity on hand
$45.9M
Total DebtLower is stronger
$49.1M
Stockholders' EquityBook value
$28.0M
$253.3M
Total Assets
$97.7M
$286.0M
Debt / EquityLower = less leverage
1.75×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLPT
CLPT
RCAT
RCAT
Q4 25
$45.9M
Q3 25
$38.2M
Q2 25
$41.5M
Q1 25
$12.4M
Q4 24
$20.1M
Q3 24
$21.6M
Q2 24
$32.8M
Q1 24
$35.4M
Total Debt
CLPT
CLPT
RCAT
RCAT
Q4 25
$49.1M
Q3 25
$29.2M
Q2 25
$28.8M
Q1 25
Q4 24
Q3 24
Q2 24
$10.0M
Q1 24
$10.0M
Stockholders' Equity
CLPT
CLPT
RCAT
RCAT
Q4 25
$28.0M
Q3 25
$15.9M
$253.3M
Q2 25
$19.7M
Q1 25
$20.0M
$28.9M
Q4 24
$25.4M
$27.0M
Q3 24
$29.0M
Q2 24
$32.1M
Q1 24
$34.6M
$49.6M
Total Assets
CLPT
CLPT
RCAT
RCAT
Q4 25
$97.7M
Q3 25
$60.4M
$286.0M
Q2 25
$62.9M
Q1 25
$30.1M
$59.7M
Q4 24
$39.2M
$51.1M
Q3 24
$40.2M
Q2 24
$52.6M
Q1 24
$53.6M
$55.3M
Debt / Equity
CLPT
CLPT
RCAT
RCAT
Q4 25
1.75×
Q3 25
1.84×
Q2 25
1.46×
Q1 25
Q4 24
Q3 24
Q2 24
0.31×
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLPT
CLPT
RCAT
RCAT
Operating Cash FlowLast quarter
$-12.1M
$-23.9M
Free Cash FlowOCF − Capex
$-12.1M
$-24.5M
FCF MarginFCF / Revenue
-116.5%
-254.2%
Capex IntensityCapex / Revenue
0.5%
6.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-24.4M
$-55.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLPT
CLPT
RCAT
RCAT
Q4 25
$-12.1M
Q3 25
$-3.1M
$-23.9M
Q2 25
$-2.6M
Q1 25
$-6.2M
$-15.9M
Q4 24
$-1.2M
$-10.1M
Q3 24
$-1.2M
Q2 24
$-2.7M
Q1 24
$-3.8M
$-4.1M
Free Cash Flow
CLPT
CLPT
RCAT
RCAT
Q4 25
$-12.1M
Q3 25
$-3.3M
$-24.5M
Q2 25
$-2.6M
Q1 25
$-6.4M
$-16.2M
Q4 24
$-1.5M
$-10.2M
Q3 24
$-1.2M
Q2 24
Q1 24
$-4.2M
FCF Margin
CLPT
CLPT
RCAT
RCAT
Q4 25
-116.5%
Q3 25
-37.5%
-254.2%
Q2 25
-28.7%
Q1 25
-74.9%
-992.9%
Q4 24
-19.4%
Q3 24
-14.9%
Q2 24
Q1 24
-71.1%
Capex Intensity
CLPT
CLPT
RCAT
RCAT
Q4 25
0.5%
Q3 25
2.2%
6.9%
Q2 25
1.0%
Q1 25
2.2%
16.8%
Q4 24
3.4%
Q3 24
0.1%
Q2 24
0.0%
Q1 24
0.0%
0.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLPT
CLPT

Neurosurgery Navigation And Therapy Disposable Products$4.7M45%
Biologics And Drug Delivery Services And License Fees$2.8M27%
Biologics And Drug Delivery Disposable Products$2.4M23%
Other$502.0K5%

RCAT
RCAT

Products$8.5M88%
Services$1.2M12%

Related Comparisons